AI Gene Therapy: Algen and AstraZeneca's $555M Deal
Update: 2025-10-06
Description
AI-powered drug discovery: Algen Biotechnologies partners with AstraZeneca in a $555 million deal to develop gene therapies for immune-related disorders. Discover how Algen's AI platform, born from CRISPR tech roots, is revolutionizing medicine and fueling AstraZeneca's $80 billion sales goal. This collaboration highlights the growing role of AI in accelerating drug development and transforming patient care.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
1.0x
